Invention Grant
- Patent Title: Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
-
Application No.: US16903882Application Date: 2020-06-17
-
Publication No.: US11000550B2Publication Date: 2021-05-11
- Inventor: Tien Lee , Hans G. Klingemann , Barry J. Simon , Laurent Boissel
- Applicant: NantKwest, Inc.
- Applicant Address: US CA San Diego
- Assignee: NantKwest, Inc.
- Current Assignee: NantKwest, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: A61K35/17
- IPC: A61K35/17 ; C07K16/28 ; C12N5/0783 ; A61K39/395 ; C07K16/32 ; A61K39/00
Abstract:
This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
Public/Granted literature
- US20200306312A1 GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBOIDES FOR THE TREATMENT OF CANCER Public/Granted day:2020-10-01
Information query
IPC分类:
